Ser351

Site Information
RPLLRsMsAAFCSLL SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 451364

In vivo Characterization
Methods used to characterize site in vivo:	[32P] bio-synthetic labeling ( 20 ) , mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 6 , 7 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 ) , microscopy-colocalization with upstream kinase ( 12 ) , mutation of modification site ( 12 , 20 ) , phospho-antibody ( 12 , 19 ) , western blotting ( 12 )
Disease tissue studied:	breast cancer ( 5 , 6 , 10 , 12 ) , breast ductal carcinoma ( 5 ) , HER2 positive breast cancer ( 3 ) , luminal A breast cancer ( 3 ) , luminal B breast cancer ( 3 ) , breast cancer, surrounding tissue ( 3 ) , breast cancer, triple negative ( 3 , 5 ) , lung cancer ( 10 ) , non-small cell lung cancer ( 10 ) , pancreatic ductal adenocarcinoma ( 7 ) , melanoma skin cancer ( 4 )
Relevant cell line - cell type - tissue:	'pancreatic, ductal'-pancreas ( 7 ) , 293 (epithelial) ( 12 ) , A549 (pulmonary) [CD38 (human), transfection, Lentiviral particles containing CD38 vector were transfected] ( 2 ) , A549 (pulmonary) ( 2 ) , breast ( 3 , 5 ) , BT-20 (breast cell) ( 10 ) , BT-549 (breast cell) ( 10 ) , Calu 6 (pulmonary) ( 10 ) , Chang liver (cervical) ( 18 ) , COS (fibroblast) ( 12 , 20 ) , H2009 (pulmonary) ( 10 ) , H2077 (pulmonary) ( 10 ) , H2887 (pulmonary) ( 10 ) , H322M (pulmonary) ( 10 ) , HCC1359 (pulmonary) ( 10 ) , HCC1937 (breast cell) ( 10 ) , HCC2279 (pulmonary) ( 10 ) , HCC366 (pulmonary) ( 10 ) , HCC4006 (pulmonary) ( 10 ) , HCC78 (pulmonary) ( 10 ) , HCC827 (pulmonary) ( 10 ) , HeLa (cervical) ( 9 , 11 , 13 , 14 , 15 , 16 , 17 , 19 ) , HMLER ('stem, breast cancer') [CXCR4 (human), knockdown] ( 6 ) , HMLER ('stem, breast cancer') ( 6 ) , HOP62 (pulmonary) ( 10 ) , LCLC-103H (pulmonary) ( 10 ) , LOU-NH91 (squamous) ( 10 ) , MCF-7 (breast cell) ( 10 , 12 ) , MDA-MB-231 (breast cell) ( 10 ) , MDA-MB-468 (breast cell) ( 10 ) , NCI-H1395 (pulmonary) ( 10 ) , NCI-H1568 (pulmonary) ( 10 ) , NCI-H157 (pulmonary) ( 10 ) , NCI-H1648 (pulmonary) ( 10 ) , NCI-H1666 (pulmonary) ( 10 ) , NCI-H2030 (pulmonary) ( 10 ) , NCI-H2172 (pulmonary) ( 10 ) , NCI-H322 (pulmonary) ( 10 ) , NCI-H460 (pulmonary) ( 10 ) , NCI-H520 (squamous) ( 10 ) , NCI-H647 (pulmonary) ( 10 ) , PC9 (pulmonary) ( 10 ) , Vero E6-S ('epithelial, kidney') ( 1 ) , WM239A (melanocyte) ( 4 )

Upstream Regulation
Putative in vivo kinases:	PRKD1 (human) ( 20 )
Kinases, in vitro:	PRKD1 (human) ( 12 , 20 )
Treatments:	phorbol_ester ( 19 )

Downstream Regulation
Effects of modification on Rin1:	intracellular localization ( 20 ) , molecular association, regulation ( 20 )
Induce interaction with:	14-3-3 beta (human) ( 20 )

References
1	Bouhaddou M, et al. (2020) The Global Phosphorylation Landscape of SARS-CoV-2 Infection. Cell 182 32645325 Curated Info
2	Wang W, et al. (2018) Decreased NAD Activates STAT3 and Integrin Pathways to Drive Epithelial-Mesenchymal Transition. Mol Cell Proteomics 29980616 Curated Info
3	Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62 27251275 Curated Info
4	Stuart SA, et al. (2015) A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells. Mol Cell Proteomics 14, 1599-615 25850435 Curated Info
5	Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704 24719451 Curated Info
6	Yi T, et al. (2014) Quantitative phosphoproteomic analysis reveals system-wide signaling pathways downstream of SDF-1/CXCR4 in breast cancer stem cells. Proc Natl Acad Sci U S A 111, E2182-90 24782546 Curated Info
7	Britton D, et al. (2014) Quantification of pancreatic cancer proteome and phosphorylome: indicates molecular events likely contributing to cancer and activity of drug targets. PLoS One 9, e90948 24670416 Curated Info
8	Shiromizu T, et al. (2013) Identification of missing proteins in the neXtProt database and unregistered phosphopeptides in the PhosphoSitePlus database as part of the Chromosome-centric Human Proteome Project. J Proteome Res 12, 2414-21 23312004 Curated Info
9	Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71 23186163 Curated Info
10	Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68 22617229 Curated Info
11	Nishioka T, Nakayama M, Amano M, Kaibuchi K (2012) Proteomic screening for Rho-kinase substrates by combining kinase and phosphatase inhibitors with 14-3-3ζ affinity chromatography. Cell Struct Funct 37, 39-48 22251793 Curated Info
12	Ziegler S, et al. (2011) A novel protein kinase D phosphorylation site in the tumor suppressor Rab interactor 1 is critical for coordination of cell migration. Mol Biol Cell 22, 570-80 21209314 Curated Info
13	Zhou J (2009) CST Curation Set: 7618; Year: 2009; Biosample/Treatment: cell line, HeLa/untreated; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986 Curated Info
14	Zhou J (2009) CST Curation Set: 7615; Year: 2009; Biosample/Treatment: cell line, HeLa/untreated; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986 Curated Info
15	Zhou J (2009) CST Curation Set: 7614; Year: 2009; Biosample/Treatment: cell line, HeLa/untreated; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986 Curated Info
16	Zhou J (2009) CST Curation Set: 6344; Year: 2009; Biosample/Treatment: cell line, HeLa/EGF; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986 Curated Info
17	Dephoure N, et al. (2008) A quantitative atlas of mitotic phosphorylation. Proc Natl Acad Sci U S A 105, 10762-7 18669648 Curated Info
18	Sui S, et al. (2008) Phosphoproteome analysis of the human Chang liver cells using SCX and a complementary mass spectrometric strategy. Proteomics 8, 2024-34 18491316 Curated Info
19	Döppler H, et al. (2005) A phosphorylation state-specific antibody recognizes Hsp27, a novel substrate of protein kinase D. J Biol Chem 280, 15013-9 15728188 Curated Info
20	Wang Y, et al. (2002) The RAS effector RIN1 directly competes with RAF and is regulated by 14-3-3 proteins. Mol Cell Biol 22, 916-26 11784866 Curated Info